1	litle: Usage and awareness of antiviral medications for COVID-19
2	
3	<b>Authors:</b> Kojima N <sup>1</sup> and Klausner JD <sup>2</sup>
4	
5	<sup>1</sup> Department of Medicine, University of California Los Angeles, Los Angeles, 90095
6	<sup>2</sup> Department of Population and Public Health Sciences, University of Southern
7	California, Keck School of Medicine, Los Angeles, 90033
8	
9	Keywords: COVID-19; SARS-CoV-2; Antiviral
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	Corresponding Author Contact Information:
22	Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA
23	90095. Email: nkojima@ucla.edu
24	

Abstract

25

27

28

29

30

31

32

We surveyed people that recently tested positive for SARS-CoV-2 to assess the

frequency and correlates of early treatment seeking behavior. Among high risk

respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought

treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection.

More public outreach is needed to raise awareness of the benefits of treatment for

COVID-19.

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

Main Text Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to cause severe disease, hospitalization, and death. There are effective means to treat SARS-CoV-2 infection [1-4], however is it not clear how often those who would benefit most use monoclonal antibodies, molnupiavir, and nirmatrelvir. We surveyed users of a national SARS-CoV-2 testing company to assess treatment awareness, treatment seeking behavior, and use of antiviral medications for those with a positive test result. We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by a reverse transcriptase polymerase chain reaction (RT-PCR) assay at a large clinical laboratory (Curative, San Dimas, CA). To be eligible, individuals had to have a positive RT-PCR test result within 7 days of enrollment. All surveys were anonymous and voluntary. We collected data on age, assess treatment awareness, treatment seeking behavior, and use of antiviral medications for COVID-19. Descriptive statistics were calculated on StataSE (StataCorp, College Station, TX). Advarra deemed the study IRB exempt (Pro00059961). There were 1,159 respondents during March 2022. Among individuals aged 65 years and older, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection (Figure). Rates were similar among younger individuals.

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Due to the timing of the survey, infections were most likely caused by either the Omicron variant of SARS-CoV-2 or a sublineage of the Omicron variant, which might be less severe in those with prior immunity [5]. Our findings demonstrate that increased awareness and use of antivirals among those at risk for severe disease due to COVID-19 are urgently needed among individuals that test positive for SARS-CoV-2. **Declarations** Declaration of competing interests NK is a consultant for Curative. JDK is an independent consultant and serves as the Medical Director of Curative. **Funding** Curative Inc. and by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation. Acknowledgements To the participants that donated their time.

## References

- 1. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV
- Antibody Combination to Prevent Covid-19. N Engl J Med 2021; 385(13): 1184-
- 77 95.

74

91

- 78 2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with
- 79 SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med **2021**; 385(21):
- 80 1941-50.
- 81 3. Whitley R. Molnupiravir A Step toward Orally Bioavailable Therapies for Covid-
- 82 19. N Engl J Med **2021**.
- 83 4. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment
- with fluvoxamine on risk of emergency care and hospitalisation among patients
- with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob
- 86 Health **2022**; 10(1): e42-e51.
- 5. Christie B. Covid-19: Early studies give hope omicron is milder than other
- 88 variants. BMJ **2021**; 375: n3144.
- 89 6. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of
- 90 serious illness, company reports. BMJ **2021**; 375: n2713.

Figure. Treatment awareness, treatment seeking behavior, and use of antiviral medications among individuals 65 years and older versus individuals younger than 65 years that tested positive for SARS-CoV-2 infection in 37 States in the United States from 1 March 2021 to 30 March 2021

